SecBot SecBot
SECBOTREPLAY Home › Report › KPTI

KPTI · GS discloses 0.9% stake

Karyopharm Therapeutics Inc. · SC 13G/A filed Nov 9, 2026 at 13:45 ET

At the news

NEUTRALIMPACT 2/10

SC 13G/A filed Nov 9, 2026 at 13:45 ET

Goldman Sachs filed an amended Schedule 13G disclosing a beneficial ownership of 203,129 shares (0.9%) of Karyopharm Therapeutics as of September 30, 2026. This is a routine passive stake update; the stake is very small relative to the company's market cap and represents no material change in investment intent.

  • Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed an amended Schedule 13G
  • Beneficial ownership: 203,129 shares (0.9%) of Karyopharm Therapeutics as of September 30, 2026
  • Stake value approximately $203,129 based on filing data
  • Filing is a routine passive stake update under Rule 13d-1(b)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access